GW Pharma
Cannabis-based treatment scores Phase 3 successes for GW Pharma
December 6, 2016Manufacturing and Production, Research and Development GW Pharma, cannabidiol
UK-based GW Pharmaceuticals, a biopharmaceutical firm focused on the development of novel cannabinoid therapies, has unveiled new efficacy data for …
GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA
April 21, 2016Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy
GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
GW Pharma shares more than double after positive Phase III trials for epilepsy drug
March 15, 2016Manufacturing and Production, Research and Development Epidiolex, GW Pharma, US FDA, epilepsy in children, phase III
Shares in UK-based GW Pharmaceuticals (Nasdaq: GWPH) more than doubled on the Nasdaq Monday after the company announced positive results …
Latest content
Five Facts about NHS and primary care
September 5, 2026
AI in pharma: From lab development to patient impact
September 5, 2026
